Old allergy drug may help repair nerves in MS patients

NCT ID NCT05338450

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether clemastine fumarate, an allergy medication, could improve eye movement problems in people with multiple sclerosis (MS). The trial planned to enroll 80 MS patients with a specific eye condition called internuclear ophthalmoparesis, but was terminated early with 47 participants. Participants took either clemastine or a placebo for 6 months, and researchers measured eye movements using infrared technology.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
clemastine fumarate (antihistamine)
What this could lead to
If it works, this could point toward a treatment that repairs nerve insulation in multiple sclerosis, potentially improving eye coordination and other symptoms.
What could go wrong
The trial was terminated early with only 47 of 80 planned participants, so results may be inconclusive. Clemastine is an older antihistamine, and its effect on nerve repair is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERNUCLEAR OPHTHALMOPLEGIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Amsterdam UMC, location VUmc

    Amsterdam, 1081 HV, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.